Dr Christopher G. Bell

Profile

ORCID iD: 0000-0003-4601-1242

Christopher Bell gained his PhD in human genomics from Imperial College London, investigating genetic susceptibility to type 2 diabetes and obesity under the supervision of Prof. Philippe Froguel. His post-doctoral training was with Prof. Stephan Beck at the UCL Cancer Institute, University College London, where they pioneered the epigenomic analysis of common human disease. This included publishing some of the very first Epigenome-wide Association Studies (EWAS) as well as ground-breaking integrative analyses of the DNA methylome within common disease-associated loci. He subsequently furthered his epigenomics expertise interrogating the deeply-phenotyped TwinsUK cohort, with Prof. Tim Spector, at King’s College London, and then as an independent group leader at the MRC Lifecourse Epidemiology Unit. He is a medical graduate of the University of Otago, New Zealand and, through training with the Royal College of Pathologists of Australasia, in Sydney, gained his fellowship of genetic pathology. 

He is an expert in human epigenomics and its role in the pathology of common disease, with a specific focus on type 2 diabetes, cardiometabolic disorders, and chronic ageing-related diseases. His research involves large-scale computational, statistical, and functional integration of multi-omic human datasets.

He is an Associate Editor for the journals ‘Epigenetics’ and ‘Clinical Epigenetics’. Also, he is a Digital Environment Research Institute (DERI) Fellow.

Research

Group members

• Dr Paraskevi Christofidou (Post-Doctoral Researcher)

Summary

Our research is focused on understanding the pathophysiology of common and chronic human diseases, by investigating and integrating large-scale epigenomic, genomic, and transcriptomic data. This knowledge will enable a more precise insight into the perturbed molecular mechanisms involved in these diseases, with the ultimate aim of identifying novel avenues for treatment and prevention.

Due to the power now available from population-based multi-omic datasets, human diseases can be directly studied at scale with the human as model. Our work centres on:

• How disease-related genetic variation impacts on the epigenome and, thereby, leads to pathological functional changes in disease-relevant cell-types. This, for example, has included defining obligatory or facilitative allelic DNA methylome variation within disease-associated loci in the human genome.
• Interrogating the ageing-related deterioration of the epigenome. Recent fascinating discoveries have revealed these changes capture aspects of ‘biological’ ageing that impact on population variability in age-related phenotypes and may bring novel mechanistic insights to chronic ageing-related diseases.
• The robust biomarker ability of DNA methylation to capture and quantitate both internal and external chronic disease-related exposures. We are investigating their predictive power in combination with ageing- and phenotype-related DNA methylation ‘clocks’ (constructed with ML methodology) as well as genetic risk scores. The aim is to determine the potential clinical utility of these biomarkers, with the analysis of longitudinal datasets taking advantage of the long-term stability of DNA modifications.

This research into metabolic disorders, type 2 diabetes and cardiovascular diseases encompasses the broad themes of epigenomics; functional genomics; computational medicine; statistical genomics, bioinformatics, and genomic medicine. We are also a core member of the cross-cutting QMUL Epigenetics Hub.

Publications

• Ramírez J, van Duijvenboden S, Young WJ et al. (2024). Fine mapping of candidate effector genes for heart rate. nameOfConference

  
  

  DOI: 10.1007/s00439-024-02684-z

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/98893
• Bell CG (2024). Quantifying stochasticity in the aging DNA methylome. nameOfConference

  
  

  DOI: 10.1038/s43587-024-00634-y

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97990
• Bell CG (2024). Epigenomic insights into common human disease pathology. nameOfConference

  
  

  DOI: 10.1007/s00018-024-05206-2

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/96180
• Maiarù M, Acton RJ, Woźniak EL et al. (publicationYear). A DNA methylation signature in the stress driver gene Fkbp5 indicates a neuropathic component in chronic pain. nameOfConference

  
  

  DOI: 10.1186/s13148-023-01569-8

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91157
• van Duijvenboden S, Ramírez J, Young WJ et al. (2023). Integration of genetic fine-mapping and multi-omics data reveals candidate effector genes for hypertension. nameOfConference

  
  

  DOI: 10.1016/j.ajhg.2023.08.009

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91151
• Saunderson EA, Encabo HH, Devis J et al. (2023). CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny. nameOfConference

  
  

  DOI: 10.1073/pnas.2300224120

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91866
• McErlean P, Bell CG, Hewitt RJ et al. (2021). DNA Methylome Alterations are Associated with Airway Macrophage Differentiation and Phenotype During Lung Fibrosis.. nameOfConference

  
  

  DOI: 10.1164/rccm.202101-0004OC

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/74816
• Acton R, Yuan W, Gao F et al. (2021). The Genomic Loci of Specific Human tRNA Genes Exhibit Ageing-Related DNA Hypermethylation. nameOfConference

  
  

  DOI: 10.1038/s41467-021-22639-6

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/71340
• Berjawi M, Bell CG (2021). The Therapeutic Potential of Epigenome-Modifying Drugs in Cardiometabolic Disease. nameOfConference

  
  

  DOI: 10.1007/s40142-021-00198-y

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/70953
• Lechner M, Schartinger VH, Steele CD et al. (2021). Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. nameOfConference

  
  

  DOI: 10.1038/s41467-020-20308-8

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/70061

Collaborators

Internal

• Prof. Patricia Munroe (CPPM, WHRI)
• Dr Miguel Branco (Blizard)

External

• Dr Sandrine Géranton (Cell & Developmental Biology; University College London)
• Dr Pirro G. Hysi (Dept. of Twin Research; King’s College London)
• Prof. Stephan Beck (UCL Cancer Institute, University College London)
• Dr Adam Byrne (National Heart & Lung Institute; Imperial College London)
• Dr Michelle Holland (Genetics & Molecular Medicine; King’s College London)
• Dr Paul Caton (Life Sciences & Medicine; King’s College London)
• Prof. Wolf Reik (Altos Labs, Cambridge, U.K.)

News

• Interview on AI-driven assessment of ‘biological’ ageing (National Geographic, USA), January 2023
• Interview on ‘Biological’ ageing (El País Newspaper, Spain), May 2022
• Outlook section– Interview on Epigenetic ‘Clocks’ (Nature), January 2022
• Comment in “Exploring the Epigenetics of Ethnicity”, (The Scientist, USA), January 2017

Disclosures

No disclosures.